These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 31988233

  • 1. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
    Scheinberg T, Kench J, Stockler M, Mahon KL, Sebastian L, Stricker P, Joshua AM, Woo H, Thanigasalam R, Ahmadi N, Centenera MM, Butler LM, Horvath LG.
    BMJ Open; 2020 Jan 26; 10(1):e033667. PubMed ID: 31988233
    [Abstract] [Full Text] [Related]

  • 2. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec 26; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D, Bardia A, Sellers WR.
    Clin Cancer Res; 2017 Jul 01; 23(13):3251-3262. PubMed ID: 28351928
    [Abstract] [Full Text] [Related]

  • 4. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET, Nölting S, Spoettl G, Maurer J, Auernhammer CJ.
    Neuroendocrinology; 2018 Jul 01; 106(1):58-73. PubMed ID: 28226315
    [Abstract] [Full Text] [Related]

  • 5. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA.
    Expert Rev Anticancer Ther; 2018 Mar 01; 18(3):201-213. PubMed ID: 29457921
    [Abstract] [Full Text] [Related]

  • 6. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr 01; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D.
    Breast Cancer Res Treat; 2017 Nov 01; 166(1):41-54. PubMed ID: 28741274
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
    Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S.
    Clin Cancer Res; 2021 Aug 01; 27(15):4177-4185. PubMed ID: 33722897
    [Abstract] [Full Text] [Related]

  • 10. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Zangardi ML, Spring LM, Blouin GC, Bardia A.
    Expert Rev Clin Pharmacol; 2017 Nov 28; 10(11):1169-1176. PubMed ID: 28875723
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
    Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U.
    ACS Chem Biol; 2015 Dec 18; 10(12):2680-6. PubMed ID: 26390342
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM, Zangardi ML, Moy B, Bardia A.
    Oncologist; 2017 Sep 18; 22(9):1039-1048. PubMed ID: 28706010
    [Abstract] [Full Text] [Related]

  • 20. Targeting CDK4/6 in patients with cancer.
    Hamilton E, Infante JR.
    Cancer Treat Rev; 2016 Apr 18; 45():129-38. PubMed ID: 27017286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.